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Abstract: Uncarinic acid C (URC) is triterpene isolated from Uncaria rhynchophylla and is a pharmacologically active substance. 
The induction of dendritic cells (DC) is critical for the induction of Ag-specific T lymphocyte responses and may be essential for 
the development of human vaccines relying on T cell immunity. DC might be a potential target for URC. We demonstrate that 
URC   activates human DC as documented by phenotypic and functional maturation, and altered cytokine production. The expres-
sion of CD1a, CD38, CD40, CD54, CD80, CD83, CD86, HLA-DR and CCR7 on URC-primed DC was enhanced. The production 
of IL-12p70 by URC-primed DC was higher than that of lipopolysaccharide (LPS)-primed DC. The production of IL-12p70 by 
URC-primed DC was inhibited by the anti-Toll-like receptor 4 (TLR4) monoclonal antibody (mAb), but partially abolished by 
anti-TLR2 mAb. mRNA coding for TLR2 and TLR4 was expressed in URC-primed DC. URC-primed DC induced the NF-κΒ 
transcription factor. Naïve T cells co-cultured with URC-primed DC turned into typical Th1 cells that produced large quantities of 
IFN-γ depending on IL-12 secretion. URC enhanced the T cell stimulatory capacity in an allo MLR. In the cytotoxic T-lymphocyte 
assay (CTL) assay, DNA fragmentation assay and 51Cr release on URC-primed DC were more augmented than that of TNF-α-primed 
DC. DC matured with URC had an intermediate migratory capacity towards CCL19 and CCL21. These results suggest that URC 
  modulates DC function in a fashion that favors Th1 polarization via the activation of IL-12p70 dependent on TLR4 signaling, and 
may be used on DC-based vaccine for cancer immunotherapy.
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Introduction
The immune system is confronted with antigens and 
proteins that have not been encountered previously. 
Due to their unique antigen processing and presen-
tation  and  high-level  expression  of  costimulatory 
and cytokine molecules, DC are highly specialized 
  antigen-presenting cells (APC) with a unique ability 
to activate resting T lymphocytes and initiate primary 
immune responses as to induce peripheral tolerance.1–3 
DC orchestrate a variety of immune responses by stim-
ulating the differentiation of naïve CD4 T cells into 
helper T effectors such as Th1, Th2 or Th17 type.4–7 
Cytokines, secreted by DC at the time of initial T cell 
stimulation, play an important role in the subsequent 
differentiation of effector T cells. Th1 cells, through 
interferon gamma (IFN-γ) production, regulate anti-
gen presentation and immunity against intracellular 
pathogens. Although different DC subsets may have 
some intrinsic potential to preferentially induce Th1, 
Th2 or Th17 cells, DC also display considerable func-
tional plasticity in response to signals from microbes 
and the local microenvironment.8 Multiple reagents 
have been reported to induce DC maturation and the 
known DC maturation stimuli include the CD40 ligand 
(CD40-L), IFN-α TNF-α, oligo CpG nucleotides1 or 
Toll-like receptor ligands.9 Toll-like receptors (TLRs) 
are expressed mainly on macrophages and DC, trig-
gering results in the development of effector DC that 
promote Th1 responses.10 Recently, several studies 
proposed  the  significance  of TLR  signaling  in  the 
induction  of  anti-cancer  immunity.  Important  aims 
of  DC  research  are  the  d  evelopment  of  DC-based 
strategies for e  nhancing immune responses against 
tumor,  infectious  agents  or  autoimmune  diseases. 
DC are being used in a number of   clinical immuno-
therapy protocols in the cancer s  etting. However, to 
date, the results of these trials seem to suggest that 
only   modest clinical b  enefits may be attributed to this 
  modality. Therefore, it is important to identify factors 
that might affect the d  ifferentiation, maturation and 
function of DC.
The hooks of Uncaria sp. are contained in   Choto-san 
as the main component herb and have been widely 
used  as  an  important  component  of  many  Chinese 
prescriptions in Asia. URC is isolated from Uncaria 
rhynchophylla  and  phytochemically  classified  as 
  triterpene. Triterpenes have been identified as a unique 
class of natural products possessing diverse biological 
  activities. We have recently reported that some terpenes 
induce DC from human monocytes and drive Th1, Th2 
or IL-10-producing Treg cells.11–14 A number of alka-
loids have been reported as antihypertensive principles 
from the genus Uncaria. URC showed potent inhibi-
tory activity against phospholipase Cγ1 (PLCγ1) and 
inhibited the growth of cancer cells at high doses.15 
Thus, although terpene compounds have pharmacolog-
ical activity, little is known about how URC influence 
the initiation of the specific immune response at the 
level of DC, the highly professional APC for T cells. 
DC might be a potential target for URC. In this study, 
we investigated the ability of URC on human DC dif-
ferentiation (surface molecule up-regulation), function 
(cytokine  productions)  and  their  activation  (NF-κB 
translocation to the nucleus) detail.
Materials and Methods
culture medium, reagents  
and monoclonal antibodies
The culture medium used in this study was serum-
free  AIM-V  medium  (Life  Technologies,  Paisley, 
UK).  Recombinant  human  IL-4  (IL-4),  recombi-
nant  human  granulocyte-macrophage  colony-stim-
ulation  factor  (GM-CSF),  anti-TLR2  mAb  and 
anti-TLR4  mAb  purchased  from  R&D  systems 
(  Minneapolis, MN). For flow cytometry, monoclo-
nal  antibodies  (mAbs)  toward  the  following  anti-
gens were purchased from Becton-Dickinson (San 
Jose, CA): anti-CD14-FITC (fluorescent isothiocya-
nate), anti-CD1a-PE (phycoerthrin), anti-CD38-PE, 
anti-CD40-FITC,  anti-CD54-PE,  anti-80-PE,  anti-
CD83-PE, anti-CD86-PE, anti-HLA-DR-FITC, anti-
CCR7 and anti-DC-Lamp-PE. Endotoxin levels in 
all agents were blow 1.0 EU/ml.
Isolation of URc from Uncaria 
rhynchophylla
URC  was  prepared  as  described  previously.15  The 
purity of URC was .99%. The endotoxin in URC 
was  removed  using  End  Trap  5/1  (Profos  AG, 
  Regensburg,  Germany).  Endotoxin  levels  in  URC 
were blow 0.05 EU/ml.
Generation of Monocyte-Derived Dc
All cell subsets were isolated from human peripheral 
blood  of  normal  healthy  donors.  Peripheral  blood 
mononuclear cells (PBMC) were first isolated from Uncarinic acid c induces Th1-promoting dendritic cells
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heparinized whole blood by Ficoll/Isopaque/1.077 g/ml 
(Pharmacia, Freiburg,   Germany) density gradient cen-
trifugation  (465  ×  g,  30  min,  22 ° C)  as  described 
  previously.11  PBMC  were  further  separated  into 
CD14+ monocytes using the magnetic activated cell 
sorter  (MACS)  according  to  the  manufacturer’s 
instructions (Miltenyi Biotec; Auburn, CA). The purity 
of  CD14+  monocytes  was  always  more  than  90%. 
Monocytes were cultured with GM-CSF (50 ng/ml) 
and IL-4 (25 ng/ml) in serum-free AIM-V medium for 
6 days. After 6 days, cells (.95% CD1a+, CD14-) 
were harvested and re-cultured in serum-free AIM-V 
medium containing GM-CSF and IL-4 for additional 
2 days with various concentrations of URC, but with 
LPS (100 ng/ml) or TNF-α (25 ng/ml). All subsequent 
tests were performed after harvesting the cells at day 8 
and  after  removing  the  above  factors  by  extensive 
washing. The medium was replenished with cytokines 
every 2 days. To determine the   production of IL-10 
and IL-12p70 by URC-primed DC, LPS-primed DC 
or TNF-α-primed DC, DC (2 × 104 cell/well) were 
stimulated  with  CD40-L  transfected  J558  cells 
(5 × 104 cell/well, kindly provided by Prof. Kalinski at 
University of Pittsburgh, PA) for 24 h. The cell-free 
supernatants were collected and frozen at -20 °C until 
measurement  of  cytokines  using  enzyme-linked 
immunosorbent assay (ELISA).
Immunophenotype studies
Dual-Color immunofluorescence flow cytometry was 
performed using the following panel of monoclonal 
antibodies: PE-conjugated antihuman CD1a, FITC-
conjugated  antihuman  CD14,  PE-conjugated  anti-
human  CD38,  FITC-conjugated  antihuman  CD40, 
PE-conjugated  antihuman  CD54,  PE-conjugated 
antihuman CD80, PE-conjugated antihuman CD83, 
PE-conjugated  antihuman  CD86,  FITC-conjugated 
antihuman  HLA-DR,  PE-conjugated  antihuman 
DC-Lamp  and  FITC-conjugated  antihuman  CCR7. 
  Negative controls were isotype-matched with irrel-
evant  monoclonal  antibodies  (Becton-Dickinson). 
Cells were re-suspended in staining medium contain-
ing PBS and 0.1% NaN3 and then fixed with 1.0% 
paraformaldehyde.  Isotype  controls  were  run  in 
  parallel. Cell debris was eliminated from the analysis 
by forward and side scatter gating. The samples were 
analyzed on FACSCalibur (Becton-  Dickinson) with 
CellQuest software (Becton-Dickinson). Ten   thousand 
cells  were  analyzed  per  sample.  The  results  were 
expressed as mean fluorescence intensity (MFI).
extraction of nuclear proteins  
and electrophoretic Mobility shift 
Assay (eMsA)
EMSA  was  performed  with  the  Gel  Shift  assay 
  system  (Promega,  EI,  USA).  Briefly,  oligonucle-
otides  with  the  consensus  sequence  for  NF-κB 
(5′-AGTTGAGGGGACTTCCCAGG-3′) were end-la-
beled with [γ-32P] adenosine triphosphate (3 mCi/mmol) 
(  Amersham  Pharmacia  Biotech,    Buckinghamshire, 
UK) using the T4 polynucleotide kinase. The labeled 
oligonucleotide was then purified in microspin G-25 
columns  (Sigma)  and  used  as  a  probe  for  EMSA. 
Nuclear extract protein (10 µg) was pre-incubated with 
the binding buffer for 5 min, followed by incubation 
with the labeled probe for 15 min at room temperature. 
Each sample was electrophoresed in a 5% nondenatur-
ing polyacrylamide gel in 0.5 × Tris-borate-EDTA buf-
fer (pH7.4) at 120 V for 5 h. After electrophoresis, the 
gel was dried and exposed to autoradiography film.
RT-pcR and Real-Time pcR
Total cellular RNA was extracted using RNeasy Mini 
kits (Qiagen GmbH, Germany), according to manufac-
turer’s recommendations. Equal amounts of RNA from 
all  samples  were  analyzed.  Reverse  transcription  of 
1 µg of RNA into cDNA was performed using Prime-
ScriptTM 1st strand cDNA Synthesis Kit (Takara Bio 
Inc, Shiga, Japan). Primers used for real-time polymerase 
chain  reaction  (PCR)  were  purchased  from  Bioneer 
(South Korea). The primers for the TLRs were designed 
using  the  Primer-BLAST  program  from  PubMed 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index). 
(hTLR2-forward:   GCCTCTCCAAGGAAGAATCC; 
hTLR2-reverse:   TCCTGTTGTTGGACAGGTCA; 
hTLR42-forward:   AAGCCGAAAGGTGATTGT-TG; 
hTLR4-reverse:   CTGAGCAGGGTCTTCTCCAC). 
The  realtime  PCR  was  performed  using  the  Corbett 
Research  Rotor-Gene  3000  (Corbett  Life  Science, 
  Germany). The reaction mixture contained 12.5 µl 2X 
QuantiTect  SYBR  Green  PCR  Master  Mix  (  Qiagen 
GmbH, Germany), 0.5 µmol/l of forward and reverse 
primer and 2 µl of cDNA in a total volume of 25 µl. 
At  each  cycle,  accumulation  of  PCR  products  was 
detected  by  monitoring  the  increase  in  fluorescence 
by   dsDNA-binding SYBR Green. After the PCR was Kim et al
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  performed,  a  melting  curve  was  constructed  in  the 
range of 55 °C to 95 °C. Data were analyzed using the 
Rotor Gene 6 analysis software. As a first step in data 
  analysis b-actin was used for normalization of all samples 
(  normalizer). As second step in data analysis we used the 
comparative Ct method (∆∆Ct method) with the f  ollowing 
  formula:  ∆Ct  =  Ct  (  target,  TLR)—Ct  (  normalizer, 
b-  actin). The comparative calculation involved finding 
the d  ifference between ∆Ct of treated-samples and the 
mean value of the ∆Ct from normal ones.
Determination of naïve T cell 
polarization by Dc
DC were co-cultured with naïve T cells (2.5 × 105   
cells/200 µl) at 1:5 DC/T cells ratio in 96-well U-bot-
tomed tissue culture plates (Costar,   Cambridge, MA). 
Briefly, naïve CD4+ T cells were isolated from allo-
geneic  PBMC  using  naïve  CD4+  T  cells  isolation 
kit  (Miltenyi  Biotec).  The  purity  of  isolated  cells 
was .95% for naïve CD4+ T cells as determined by 
flow  cytometry  using  FACSCalibur.  Some  cultures 
were  supplemented  with  neutralizing  Abs  to  block 
endogenous  cytokines:  anti-IL12  mAb  (10  µg/ml, 
R&D systems). On day 5, cells were washed out com-
pletely and expanded with fresh medium c  ontaining 
10 U/ml of rIL-2 (R&D Systems). One hundred micro-
liters of culture supernatant was replaced with medium 
of the same concentration every 3 days. On day 14, 
cells were washed, counted and T cells (106/ml) were 
re-stimulated  for  24  h  with  Dynabeads  CD3/CD28 
T cell expander (Invitrogen). The cell-free supernatants 
were collected and frozen at –20 until measurement of 
cytokines using ELISA.
Allogeneic Mixed Lymphocyte Reaction
CD4+ naïve T cells for the allogeneic mixed lym-
phocyte  reaction  assay  were  obtained  from  allo-
geneic  PBMC  using  magnetic  cell  sorting  and 
separation of biomolecules (MACS) beads (Miltenyi 
Biotec). The purity of isolated cells was .95% of 
CD4+ naïve T cells as determined by flow cytometry 
using   FACSCalibur. Allogeneic CD4+ naïve T cells 
(5 × 104 cell/well) were co-cultured in 96-well round-
  bottomed culture plates with graded doses (2 × 102 to 
5 × 104) of irradiated (30 Gy) DC. After 5 days, cells 
were pulsed with 1 µCi [3H]-methylthymidine per 
well for 16 h, then harvested and analyzed in a   liquid 
scintillation counter.
cytotoxic T-lymphocyte (cTL) Assay
Details of the method used in this assay have been 
described previously.16 Briefly, DC (2 × 105) cultured 
from monocytes of HLA-A0201 donors were loaded 
with 20 µg/ml WT-1 peptide for 2 h at 37 °C in 5% CO2. 
WT-1 peptide can bind to HLA-A0201 as reported by 
Pinifla-Ibarz et al.17 In 24 well plates, autologus CD8+ 
T cells were co-cultured as effector cells 5:1 with DC 
in 2 ml of medium (RPMI1640:AIM-V = 1:1) con-
taining  10%  FBS  and  1%  penicillin-  streptomycin 
supplemented with 10 U/ml IL-2 and 5 ng/ml IL-7 
for  10  days.  After  10  days,  CD8+  T  cells  were 
  re-stimulated  with  irradiated  (25Gy)  autologus 
monocytes (2:1) which were loaded with WT-1 pep-
tides and then cells were cultured in 2 ml of medium 
containing 10% FBS and 1% penicillin-streptomycin 
supplemented with 10 ng/ml IL-2 and 5 ng/ml IL-7 
for  another  10  days. The T2  cells  (HLA-A0201+) 
were used as target cells. T2 cells (5 × 105 cells/ml) 
were loaded with 20 µg/ml of WT-1 peptide or of 
HIV-1 peptide (unrelated peptide) and incubated for 
2 h at 37 °C in 5% CO2.
DnA Fragmentation Assay
To analyze target-induced CTL apoptosis, 8 h [3H]-
methylthymidine  DNA  fragmentation  (JAM)  assay 
was performed as described previously.18 CTL were 
labeled  with  5  µCi  of  [3H]-methylthymidine  per 
106 cells 18 h prior to the assay in the absence of IL-2 
and served as the target for tumor cells. The CTL 
(3 × 104 cells/well) were co-cultured with tumor cells 
(T2) at 37 °C in 5% CO2 at various tumor-to CTL 
ratios for 8 h, then harvested and analyzed in a liquid 
scintillation counter (Beckman). Data are expressed as 
a percentage of DNA fragmentation based on the per-
centage decrease in cpm as compared with untreated 
controls using the following formula: % DNA frag-
mentation  =  (Control  cpm-Sample  cpm/Control 
cpm) × 100. This assay was done in triplicate.
51cr Release Assay
Details of the methods used in this assay have been 
described  previously.19  Briefly,  effector  cells  were 
incubated with 51Cr labeled target cells (1 × 104) at 
various effectors-to target cell ratios for 6 h, followed 
by supernatant harvesting for measuring r  adioactivity 
using automatic γ counter. This assay was done in 
triplicate.Uncarinic acid c induces Th1-promoting dendritic cells
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chemotaxis
DC migration was performed in 24-well transwell cell 
culture  chambers  (5-µm  pore;  Costar)  as  described 
  previously.12 105 cells were washed, suspended in RPMI 
1640 supplemented with 10% FBS medium and loaded 
in the upper chamber compartment, CCL19 (250 ng/ml; 
Peprotech), CCL21 (250 ng/ml; Peprotech) or without 
chemokines (medium) were added to the lower com-
partment. After 4 h of incubation at 37 °C, cells that had 
migrated into the lower compartment were collected and 
counted. The results were expressed as net migration 
percent calculated as: (the number of cells that migrated 
into the lower chamber containing chemokine-number 
of cells that migrated in medium alone)/total number of 
cells loaded in the upper chamber × 100.
statistical Analysis
Statistical analysis of the results was performed by 
ANOVA.  Differences  were  considered  statistically 
significant when P value were less than 0.05.
Results
Urc induced human monocyte-derived Dc
In order to study the direct effect of URC on the f  unction 
of human DC, immature monocyte-derived DC were 
exposed to URC, and phenotypical and f  unctional DC 
maturation  was  analyzed.  Human  monocytes  were 
cultured with GM-CSF and IL-4 for 6 days under 
standard conditions, followed by an a  dditional 2 days 
in  the  presence  of  various  c  oncentrations  of  URC 
(0.001–10 µM). Under these conditions, we found 
that CD1a, CD38, CD40, CD54, CD80, CD83, CD86, 
HLA-DR and DC-Lamp expression levels on URC-
primed DC were enhanced. Typical phenotype results 
are shown in Figure 1. The viability of cells treated 
with a concentration of 10 µM of URC was 95%. As 
a positive control, human monocytes were cultured 
with GM-CSF and IL-4 for 6 days,   followed by an 
additional 2 days in the presence of LPS (100 ng/ml) 
or TNF-α (50 ng/ml). LPS and TNF-α are a known 
DC  maturation-enhancing  factor.  The  expression 
levels of CD1a, CD38, CD40, CD54, CD80, CD83, 
CD86, HLA-DR, CCR7 and DC-Lamp determined by 
MFI on LPS-primed DC and TNF-α-primed DC were 
also found to be strongly enhanced (Fig. 1). I  mmature 
DC  (with  medium)  were  g  enerated  by  c  ultivating 
human monocytes with GM-CSF and IL-4 for 8 days 
served as a control. The expression level of CD14 as 
expressed by MFI on day 8 was found to be low and 
even undetectable in some s  amples (data not shown).
effects of Anti-TLR2 mAb and  
Anti-TLR4 mAb on cytokine 
production by URc-primed Dc
As DC serve as the professional antigen-presenting 
cells  and  that  their  secretion  of  immunoregulatory 
and proinflammatory cytokines plays a crucial role in 
T cell priming, we next investigated whether cytokine 
production  by  human  monocyte-derived  DC  was 
affected by treatment with URC. It has been reported 
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Figure 1. Phenotype of Dc differentiated with Urc, LPS or TnF-α. Dc were generated by stimulating immature Dc with Urc (0.1 µM), LPS (100 ng/ml) 
or TnF-α (25 ng/ml) and then were stained with FITc- or Pe-conjugated Abs against cD1a, cD38, cD40, cD54, cD80, cD83, cD86, hLA-Dr, ccr-7 
and Dc-Lamp as described in materials and methods. Antibodies were overlayed with their isotype control. Data are one experiment representative of 
four independent experiments.Kim et al
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that the level of IL-12 production by DC is a major 
factor driving the development of Th1 cells. There-
fore, we measured IL-12p70 production in immature 
DC and in DC matured for 2 days in the presence of 
the above factor following stimulation with CD40-L 
transfected J558 cells for 24 h. Major enhancements 
of IL-12p70 production were caused by 0.1 µM of 
URC  (Fig.  2A),  whereas  with  LPS-primed  DC  or 
TNF-α-primed DC only small increases can be seen 
(Fig. 2A). The concentrations of URC were used at 
0.1 µM for subsequent experiments. In contrast, the 
production of IL-12p70 by immature DC was low 
(Fig. 2A).
Toll-like  receptor  (TLR)  agonists  are  potent 
activators of innate immune responses, activating 
DC maturation and inflammatory cytokine secre-
tion by innate cells. We next examined whether the 
ability  of  IL-12  production  by  URC-primed  DC 
depended on TLRs signaling. Before stimulation 
with URC, monocyte-derived DC were incubated 
in the presence of the TLR2 mAb or TLR4 mAb 
or an isotype control (IgG). The anti-TLR4 mAb 
inhibited  IL-12p70  production  by  URC-primed 
DC or LPS-primed DC by 65%–80% (Fig.  2B), 
whereas  anti-TLR2  mAb  partially  influenced 
IL-12p70  production  by  URC-primed  DC  (Fig. 
2B). In contrast, the anti-TLR2 mAb did not affect 
IL-12p70 production by LPS-primed DC (Fig. 2B). 
The response to TNF-α was not i  nhibited in the 
  presence of the   anti-TLR2 mAb and anti-TLR4 mAb 
(Fig. 2B). IL-12p70 production by URC-, LPS- or 
TNF-α-primed DC was not influenced when IgG1 
was  added  instead  of  anti-TLR2  mAb  or  anti-
TLR4 mAb (Fig. 2B).
URc-primed Dc Induced nF-κB 
Activation and TLR expression
DC  activation  and  maturation  driven  by  TLR 
  agonist such as LPS has been clearly associated to 
NF-κB activation. To determine whether URC uses 
s  imilar a  ctivation pathways, we monitored its abil-
ity to a  ctivate of the NF-κB translocation into the 
nucleus. DC were cultured in the presence of URC 
for 30 min, 1 h and 2 h, and nuclear extracts were 
analyzed for NF-κB content. As shown in Figure 3A, 
URC was able to induce NF-κB translocation and 
activation. Similar results were obtained with LPS-
primed DC (Fig. 3A). The expression of TLR2 and 
TLR4  on  monocytes,  immature  DC,  URC-primed 
DC and LPS-primed DC was further analyzed by 
real-time quantitative RT-PCR, because of their dif-
ferent s  elective e  xpression on DC. Monocytes and 
immature DC expressed the   highest levels of TLR2 
and TLR4 on the cell p  opulation examined. mRNA 
expression of these two receptors was d  ramatically 
down-regulated  upon  d  ifferentiation  of  monocytes 
into  DC  after  8  days  of  culture  with  GM-CSF, 
IL-4 plus LPS or URC (Fig. 3B). URC-primed DC 
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Figure 2. A) IL-12p70 production by cD40-L transfected J558-stimulated Dc. Dc were generated by stimulating immature Dc with Urc (0.01–1 µM), LPS 
(100 ng/ml) or TnF-α (25 ng/ml). cells were stimulated with the cD40-L transfected J558 cells for 24 h. After 24 h, the production of IL-12p70 was measured 
by eLISA in culture supernatants. iDc, immature Dc. Data are the mean ± S.e.M. of four independent experiments. *P , 0.05 compared with immature Dc. 
B) IL-12p70 production by Urc-primed Dc was inhibited anti-TLr2 mAb and anti-TLr4 mAb. Dc were generated by stimulating immature Dc with Urc-
primed Dc (0.1 µM), LPS-primed Dc (100 ng/ml) or TnF-α-primed Dc (25 ng/ml). cells were stimulated with the cD40-L transfected J558 cells for 24 h. 
After 24 h, the production of IL-12p70 was measured by eLISA in culture supernatants. iDc, immature Dc. Data are the mean ± S.E.M. of five independent 
experiments. *P , 0.05 compared with without mAb.Uncarinic acid c induces Th1-promoting dendritic cells
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expressed c  onsiderable levels of TLR2 and TLR4. 
In  URC-primed  DC,  T  LR4  expression  seemed  to 
be more prominent than TLR2 (Fig. 3A and B). The 
expression of TLR4 on URC-primed DC was higher 
than  that  of  LPS-primed  DC.  These  data  suggest 
that URC might activate by DC via a TLR4 and/or 
TLR2 signaling.
URc-primed Dc promote the 
Differentiation of naïve T cells  
into Th1 cells
We  next  evaluated  the  nature  of  primary  alloge-
neic  T  cell  responses  stimulated  by  URC-primed 
DC. A  llogeneic URC-, LPS- or, TNF-α-primed DC 
induced  a  substantial  increase  in  the  secretion  of 
IFN-γ by T cells (Fig. 4A), but had little effect on 
IL-4   secretion (Fig. 4B) and IL-13 secretion (data 
not shown). DC differentiated with URC co-cultured 
with  naïve  T  cells  turned  into  typical  Th1  cells. 
This p  attern of IFN-γ production by naïve T cell co-
cultured with URC-primed DC were similar to the 
production  of  IL-12p70  by  URC-primed  DC.  On 
the other hand, the production of IFN-γ and IL-4 by 
naïve T cells co-  cultured with immature DC was low 
(Fig. 4A and B).
To analyze the contribution of DC-derived IL-12 
on the development of Th1 cells, we investigated the 
effect of a neutralizing anti-IL-12 mAb in co-cultured 
experiments, where naïve T cells were co-cultured with 
URC-primed DC. In URC-primed DC, neutralization 
of IL-12 increased the development of IL-4 produc-
ing T cells and decreased the development of IFN-γ 
producing  T  cells  (Fig.  4A  and  B).  Similar  results 
were obtained with LPS-primed DC (Fig. 4A and B). 
On the other hand, the production of IFN-γ and IL-4 by 
naïve T cells co-cultured with TNF-α-primed DC was 
not influenced by anti-IL-12 mAb (Fig. 4A and B).
Immunostimulatory capacity in an 
Allogeneic Mixed Lymphocyte Reaction
The ability to induce allogeneic T cell proliferation 
is a functional hallmark of DC in vitro. Changes in 
surface marker expression were also observed at a 
functional  level,  when  analyzing  the  allostiumula-
tory capacity of DC in an allo MLR. URC-primed 
DC demonstrated a higher stimulatory efficiency in 
an allo MLR than immature DC, LPS-primed DC or 
TNF-α-primed DC (Fig. 5). Co-culture of T cells with 
URC-primed DC resulted in an enhancement of T cell 
proliferation, indicating that URC potentiate the Ag-
presenting activity of DC in an allo MLR.
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binding activity using eMSA. 1: competition (×100 cold) negative control 
2: immature Dc (0 min), 3: immature Dc (30 min) 4: immature Dc (1 h) 
5: immature Dc (2 h) 6: LPS (0 min) 7: LPS (30 min) 8: LPS (1 h) 9: LPS 
(2 h) 10: Urc (0 min) 11: Urc (30 min) 12: Urc (1 h) 13: Urc (2 h). 
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ing the stimulation of Dc between LPS and Urc. Data are the mean ± 
S.e.M. of three independent experiments.
note: *P , 0.05 compared with immature Dc.
Abbreviations: Mnc, monocytes; iDc, immature Dc; Urc, Uncarinic 
acid c.Kim et al
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Dc Generated with URc Augment the 
cytotoxicity of cD8+ T cells Against 
T2 Target cells
We compared the CTL responses of autologus CD8+ 
T  cells  supported  by  DC  differentiated  with  URC 
(0.1 µΜ) or TNF-α. In an 8 h JAM assay to measure 
CTL apoptosis by tumor cells, T2 cells loaded with 
WT-1 peptides strongly induced DNA fragmentation 
of CTL that were generated with URC-primed DC 
pulsed with WT-1 peptides (Fig. 6A). Percentage of 
DNA fragmentation was dependent on the increased 
number of CTL cells. Similar results were obtained 
with a  51Cr release assay to measure lysis of target 
cells (Fig. 6B). On the other hand, percentage of DNA 
fragmentation in JAM assay and 51Cr release were low 
or undetectable when T2 loaded with HIV-1 peptide 
(unrelated peptide) and T2 (without peptides) were the 
target cells (negative control) (Fig. 6A and B).
URc-primed Dc are capable  
to Migrate
Since the other important requirement for DC efficient 
immunotherapy is the capacity to migrate towards the 
lymph node, we also studied the migratory capacity of 
DC toward CCL19 and CCL21 in vitro. As expected 
from  the  result  of  CCR7  expression,  we  observed 
migration response towards CCL19 and CCL21 in the 
URC-primed DC (Fig. 7). In contrast, the observed 
migration  response  towards  CCL19  and  CCL21  in 
TNF-α-primed DC and immature DC was found to be 
low (Fig. 7). URC-primed DC induced the expression 
of CCR7, the differences observed in the migration 
assay stress the importance of assaying the function-
ality of the expressed CCR7 in a migration assay, in 
order to assess the actual migratory capacity of DC.
Discussion
In this study, we investigated whether URC was able 
to alter the phenotype and function of DC derived from 
human  monocytes  in  vitro.  Here,  we  demonstrated 
that culture of immature DC with URC revealed up- 
regulation of the surface expression of costimulatory 
and  HLA  molecules.  URC-primed  DC  functionally 
enhanced T cell stimulatory activity in an allo MLR. 
Furthermore,  DC  generated  with  URC  induced 
Th1 cells. In addition, URC showed a good capacity 
to migrate towards CCL19 and CCL21, and showed 
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hereby both in vitro characteristics that are important 
for optimized DC for immunotherapy, the capacity to 
migrate and to produce IL-12p70 upon CD40 ligation.
The differentiation of monocytes into DC has a 
critical impact on the immune response and DC plays 
a  critical  role  in  directing  different  effector T  cell 
responses.1,3 The interaction of T cells with DC is 
crucial  for  directing  T  cell  d  ifferentiation  towards 
the Th1, Th2 or Th17 cell type.4,20 Th1 and Th2 cells 
represent  terminally  differentiated  effector  cells 
c  haracterized by a different cytokine p  roduction and 
homing capacity.21,22 It showed that URC-primed DC 
polarized into Th1 via high IL-12p70 secretion upon 
CD40-L (T cells e  ngagement) stimulation, since the 
production of IFN-γ from Th cells by URC-primed 
DC  was  affected  by  the  presence  of  n  eutralizing 
anti-IL-12 mAb. IL-12 p  roduction by DC is a major 
inducer  of  IFN-γ  and  IL-12p70  is  the  cytokine 
responsible  for  DC-  mediated  Th1  p  olarization, 
and for the e  nhancement of a  ntitumor responses of 
T  l  ymphocytes. The Th1  cells  that  produce  IFN-γ 
have been shown to exert a p  owerful antitumor effect. 
Similar results were obtained with LPS-primed DC. 
The  production  of  IL-12p70  and  IFN-γ  by  URC-
primed DC was more strongly enhanced than that 
of  LPS-primed  DC  and TNF-α-primed  DC.  IL-12 
plays a central role in the immune system, not only 
by augmenting the cytotoxic activity of T cells and 
NK cells and regulating IFN-γ production, but also 
by the capacity of IL-12 to promote the development 
of Th1 cells.23–25 Therefore, it suggests that the effect 
of URC on the production of IL-12p70 by DC and 
strengthening of the Th1 response by naïve T cells 
might  contribute  to  a  potential  antitumor  effect  of 
URC. The rationale for selecting IL-12 production as 
a potency assay for DC generated for human therapy 
is based on IL-12 properties and its confirmed role in 
host defense against pathogens and cancer. The gen-
eration of effective antitumor immunity involves the 
production of Th1 cytokines such as IL-12 and IFN-γ 
that might facilitate the induction and/or activation of 
tumor Ag-specific CD4 and CD8 cells. URC-primed 
DC provide the proinflammatory cytokines needed 
for T cell activation and Th1 development. It seems 
that  TNF-α-primed  DC  drive  the  differentiation 
of naïve T cells towards Th1 cells via an unknown 
  factor, because TNF-α-primed DC did not increase 
the IL-12 production upon CD40-L.
The  understanding  of  mechanisms  controlling 
IL-12 induction by adjuvants in general and URC in 
particular may contribute to improving their impact 
on  cellular  immune  responses  in  human  therapies. 
Recent studies have demonstrated that the signaling 
via TLR which are newly identified receptor mole-
cules recognizing many pathogens, is involved in the 
induction  of  anti-cancer  immunity.30 An  important 
immunomodulatory property of TLR agonists is their 
capacity to enhance the IL-12 production from DC 
and other innate immune cells and consequently their 
ability to promote Th1-type responses, which play a 
key protective role in immunity to tumor.26 TLR2 and 
TLR4 signaling frequently enhances the production 
of IL-12, a major Th1-inducing cytokine, on DC. We 
evaluated the role for TLRs in the development of 
Th1 cells induced by URC-primed DC. In this study, 
we found that anti-TLR2 mAb and anti-TLR4 mAb 
inhibited the production of IL-12p70 by URC-primed 
DC and influenced the production of Th1 cytokines 
from  naïve  T  cells  co-cultured  with  URC-primed 
DC.  The  inhibitory  effect  of  anti-TLR2  mAb  in 
IL-12p70 production by URC-primed DC was weak. 
We detected mRNA expression of TLR2 and TLR4 
on  URC-primed  DC.  However,  the  magnitude  of 
TLR4 expression on URC-primed DC seemed to be 
higher than the TLR2 expression. Interestingly, we 
found that upon URC and LPS stimulation, mRNA 
expression of TLR2 and TLR4 was down-regulated 
with overall mRNA transcript detection levels being 
lower than in immature DC. It has been reported that 
monocyte-  derived immature DC down-regulate TLR2 
and TLR4 upon maturation with the c  orresponding 
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c  ognate ligand LPS.27 Our experimental data s  upport 
their observations showing that LPS in human DC and 
monocytes express different mRNA TLR transcripts. 
One  might  speculate  that  URC-induced  regulation 
of TLR2 and TLR4 expression may be involved in 
positively or negatively modulating the recognition 
of URC motifs by TLR2 and TLR4. URC and LPS 
were, in part, involved in down regulation of human 
TLR. It has been reported that TLR2 and TLR4, when 
exposed to LPS, can lead to NF-κB activation and DC 
maturation.28 Our experiments showed that common 
signaling pathways are activated by URC and LPS, as 
they both induce NF-κB activation and m  odulate TLR 
expression. From an antibodies e  xperiment results, it 
appears likely, that URC-primed DC drive Th1 cell 
polarization via the activation of IL-12p70 dependent 
on TLR4 and/or TLR2 signaling.
DC are professional APC that are required for the 
initiation of immune responses. In the i  mmunotherapy 
against malignant diseases, it has been suggested that 
the induction of tumor antigen-specific CTL is most 
important  for  eliminating  tumor  cells.  Antitumor 
immunity has classically been measured by the quan-
tity of tumor-antigen-specific CD8+ T cells.29 In this 
context, it is important to know whether URC-primed 
DC enhanced specific CTL responses. As expected 
from their Th1-polarizing effect, the DC differenti-
ated with URC induced a stronger CTL response than 
immature DC or TNF-α-primed DC. DC a  ctivated with 
TLR agonists, especially TLR4 and TLR8 a  gonists 
stimulate  IL-12-p  roducing  human  myeloid  DC, 
which   activate CD8 CTL against tumors.10 Moreover, 
Kawasaki et al30 have reported that TLR4 mediates 
LPS-mimetic signal t  ransduction by an anti-cancer 
agent Taxol, a plant-derived d  iterpene, in mice but not 
human. More recently, synthetic ligands for TLR4, 
TLR7 or TLR9 have been through p  reclinical evalua-
tion and clinical t  rials against cancer.9 It suggests that 
TLR ligands are useful applications for immunother-
apy for cancer patients. T  herefore, our results suggest 
that URC is a p  romising approach for the treatment 
of cancer.
The ability of DC to migrate to mature local lymph 
nodes  and  their  subsequent  presentation  of  antigen 
to T cells plays an essential role in the initiation of 
  adaptive  immunity.  In  tissue  mature  DC  must  be 
responsive to lymph node derived signals, but must 
also be able to down-regulate tissue anchoring p  roteins 
including E-cadherin that would be to detrimental DC 
migration and antigen presentation to naïve T cells. 
  URC-primed DC had up-regulated the expression of 
CCR7 and an intermediate migratory capacity towards 
CCL19 and CCL21, suggesting that URC-primed DC 
have the potential to migrate in vivo. In most clini-
cal trials using DC-based immunotherapy, immature 
monocyte-derived DC pulsed with tumor antigen pep-
tides were used. Recent studies reported that mature 
DC could be a better antitumor adjuvant.31 However, 
there is no clear answer, yet.
Because  Polymyxin  B  is  LPS  inhibitor,  we 
i  nvestigated the effect of Polymyxin B on IL-12p70 
  production by URC or LPS. Polymyxin B completely 
inhibited the LPS-induced IL12p70 (data not shown). 
In  contrast,  the  same  treatment  did  not  affect  the 
  production of IL-q12p70 by URC-primed DC, ruling 
out the possible contamination with LPS.
Several  mechanisms  have  been  proposed  to 
explain the apparent adjuvant effects of TLR a  gonists 
on a  ntitumor immunity. TLR trigger the secretion 
of  critical  cytokines,  and  TLR  can  stimulate  the 
  proliferation of CD4+ T cells and CD8+ T cells. 
M  oreover, TLR signaling frequently enhances the 
production of IL-12 on DC. Thus, it is strongly sug-
gested that DC matured by TLR stimulation may 
induce  T  cell  d  ifferentiation  toward  Th1  by  pre-
senting antigens to T cells while promoting a Th1-
  leading situation in the local e  nvironment. Several 
TLR  agonists  have  been  d  eveloped  as  anticancer 
drugs. We expect to be able to correlate the in vitro 
DC product attributes with in vivo   immunologic and 
clinical end points.
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